562 / 1835
Rationale for use of R-CODOX –M and R-IVAC in poor
risk DLBCL (IPI 3-5):
►
Modified Magrath Burkitt Regimen
►
Dose intensity is delivered from day 1
►
Intense CNS directed therapy is achieved
•
2 doses of Rituximab given with each R-CODOX and 1 with each R-IVAC ( TOTAL 8
doses )
•
Pegylated G-CSF (NEULASTA) was given on D13 (cycle 1 & 3) and D7 (cycles 2 & 4).
R-CODOX
R-CODOX
R-IVAC
R-IVAC
R
R
R-CODOX-M + R-IVAC:UK Study
(McMillan et al ICML 2015)